DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome FARMINGDALE, N.Y., May 03, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...